A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial

Relapsed or refractory primary central nervous system lymphoma (rrPCNSL) confers a poor prognosis with no accepted standard of care. Very few prospective studies have been conducted in this patient group. This study was a multicenter phase 1/2 study that investigated thiotepa in combination with ifo...

Descripción completa

Detalles Bibliográficos
Autores principales: Fox, Christopher P., Ali, Ayesha S., McIlroy, Graham, Thust, Steffi, Martinez-Calle, Nicolás, Jackson, Aimee E., Hopkins, Louise M., Thomas, Catherine M., Kassam, Shireen, Wright, Josh, Chaganti, Sridhar, Smith, Jeffery, Chau, Ian, Culligan, Dominic, Linton, Kim M., Collins, Graham P., Ferreri, Andrés J. M., Lewis, David, Davies, Andrew J., Johnson, Rod, Auer, Dorothee P., Cwynarski, Kate
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945638/
https://www.ncbi.nlm.nih.gov/pubmed/34464973
http://dx.doi.org/10.1182/bloodadvances.2021004779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945638/
https://www.ncbi.nlm.nih.gov/pubmed/34464973
http://dx.doi.org/10.1182/bloodadvances.2021004779

Ejemplares similares